CYP2D6 pharmacogenomics of tamoxifen treatment

Technol Eval Cent Assess Program Exec Summ. 2014 Jan;28(8):1-4.
No abstract available

MeSH terms

  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics
  • Cytochrome P-450 CYP2D6 / administration & dosage*
  • Cytochrome P-450 CYP2D6 / genetics
  • Cytochrome P-450 CYP2D6 / therapeutic use
  • Drug Approval
  • Female
  • Genotype
  • Humans
  • Neoplasm Recurrence, Local / enzymology*
  • Pharmacogenetics / methods*
  • Randomized Controlled Trials as Topic
  • Tamoxifen / administration & dosage
  • Tamoxifen / therapeutic use*
  • Technology Assessment, Biomedical
  • Treatment Outcome
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen
  • Cytochrome P-450 CYP2D6